A study evaluating prognostic value of FDG-PET for survival outcomes and comparing TLG-S to EORTC criteria and PERCIST criteria for predicting 2-year survival outcomes in patients with advanced lung adenocarcinoma treated with erlotinib.
Phase of Trial: Phase II
Latest Information Update: 08 Mar 2017
At a glance
- Drugs Erlotinib (Primary)
- Indications Adenocarcinoma; Lung cancer
- Focus Therapeutic Use
- 08 Mar 2017 New trial record